6 results about "TRAIL Protein" patented technology

The invention discloses an MSLN CAR-T cell for expressing TRAIL protein and application of the MSLN CAR-T cell, and relates to the technical field of biological medicine. Spatial epitopes of tumor antigens serve as target spots, anti-tumor factors TRAIL are tried to be combined for design, the optimal combination mode of the tumor antigens and the TRAIL is searched for to play the anti-tumor role to the maximum extent, and finally it is found that when mesothelin (MSLN) serves as the target spot for designing CAR molecules, an MSLN antibody scfv region, a transmembrane region and an intracellular signal region are connected in series, and structural optimization and transformation are conducted on the MSLN antibody scfv region, the transmembrane region and the intracellular signal region; after a TRAIL coding sequence is connected to an intracellular signal region, an MSLN CAR molecule for expressing TRAIL protein is obtained, and a novel CAR-T cell therapy is developed. In-vitro and in-vivo experiments show that the treatment effect of the MSLN-TRAIL CAR-T is superior to that of second-generation MSLN CAR-T and other combination modes, the molecule can enable MSLN and TRAIL to have a synergistic effect, the immune effect of the CAR molecule is greatly improved, and an effective treatment strategy is provided for tumor patients.

The invention provides an engineering bacterium of a recombinant soluble TRAIL protein, an expression and purification method and application thereof, and belongs to the technical field of gene engineering. The method comprises the following steps: inserting a TRAIL gene between Nde I and Xho I restriction enzyme cutting sites of a pET-32a (+) vector to construct a recombinant plasmid; and transferring the recombinant plasmid into escherichia coli BL21 (DE3) to obtain an engineering bacterium for expressing the recombinant soluble TRAIL protein. The invention further provides an expression and purification method of the recombinant soluble TRAIL protein based on the engineering bacterium, the yield of the recombinant soluble TRAIL protein is improved by optimizing induction conditions, the recombinant soluble TRAIL protein with high purity and high biological activity is obtained by optimizing purification conditions, and support is provided for clinical application of the recombinant soluble TRAIL protein.

The application belongs to the technical field of biomedicine, and discloses a detection kit based on a beta-trail protein monoclonal antibody and application thereof. The application provides two strains of monoclonal antibodies which specifically recognize different antigen epitopes of the beta-trail protein, have high affinity and good specificity, and can be used for detection of the beta-trail protein. The application also provides a beta-trail protein detection kit with good performance, which has a wide linear range, high precision, good repeatability and strong applicability. The detection kit prepared by using the monoclonal antibody can be applied to kidney disease screening detection, disease monitoring, prognosis evaluation and the like.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

A fusion nanoprotein is provided wherein TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment and exhibits enhanced cancer targeting using a cancer-targeting peptide. The fusion protein effectively targets cancer cells when injected into a blood vessel, leading to TRAIL-induced cancer cell death. This fusion nanoprotein addresses key challenges of TRAIL proteins by improving their stability and reducing off-target effects through stable delivery of TRAIL trimers specifically to cancer tissues. The enhanced stability and targeted delivery properties make this fusion protein a promising candidate for development as an anticancer therapeutic agent.

This invention belongs to the field of biomedicine and relates to nanobodies. The amino acid sequence of the anti-trail nanobody is shown in SEQ ID No. 1. It can also be a tandem antibody composed of two or more repeating anti-trail nanobodies. The nanobody has a small molecular weight, strong tissue penetration, and high affinity. The anti-trail nanobody of this invention has good binding affinity to human trail protein, and it also exhibits good trail-DR5 pathway blocking activity, significantly reducing cerebral ischemia-reperfusion injury after cerebral infarction, and has broad clinical application prospects.